Caraway Therapeutics Revenue and Competitors

Caraway's targeted approaches leverage genetic data and unique biological understanding to develop small molecules that activate neurons' clearance and recycling processes – accelerating removal of toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal processes that normally maintain order inside neurons, and the risk of deterioration that occurs in neurodegenerative diseases. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative disease including Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS) and lysosomal storage diseases.